Notes: 

RELATE-2 

RELATE-2 is a UK-wide observational study that enables patients to self-register and provide consent to take part in a Real World Evidence investigation about their treatment experience. The 18-month study applies the clinically-validated OWise breast cancer mobile and web app to evaluate the feasibility, acceptability, and perceived impacts on patient experience, treatment use, and quality of care of the OWise app designed for patients undergoing treatment with TDX-d for advanced Human Epidermal Growth Factor Receptor-2 (HER-2) positive and olaparib for germline-BRCA1/2 mutated early breast cancer patients.  

RELATE-2 has been designed to provide valuable insights into the integration of treatment-support OWise app versions into routine breast cancer care, improving patient experience while contributing to robust real-world evidence generation for new breast cancer treatments. 

For more information about RELATE-2 please contact RELATE2@astrazeneca.com.  

OWise 

Developed by Px Healthcare, OWise stands as a clinically-validated patient support app platform designed to support individuals from the first day of a cancer diagnosis. With different apps for breast and prostate cancer patients, OWise supports users with a suite of medical evidence-based self-management and clinical communication tools.  

OWise supports patients with symptom tracking, medication management, informed decision-making, and communication with their physician while promoting better-informed treatment management. 

Global Impact and Real World Evidence Research: Already embraced by tens of thousands of patients globally, OWise is applied to conduct nationwide real-world evidence research, reducing the burden on healthcare services. Accessible from any mobile or web-enabled device, OWise offers a seamless approach to clinical trial participation, surpassing traditional recruitment methods. As the app is already in the pockets of patients, recruitment and activation are quick and seamless, fostering inclusivity and reducing health information barriers. 

Support and Equality: The support and information available through the OWise app contribute significantly to removing barriers to health information. By placing this resource directly in the hands of patients, OWise actively promotes health equality. Patients, regardless of their location or background, can access the support and participate in clinical research, fostering a more equitable landscape in healthcare.  

For more information about OWise please visit https://owise.uk or contact Px Founder and CEO Dr. Anne Bruinvels at anneb@pxhealthcare.com   

Instagram: @owisebreast | Twitter: @owisebreast  | Facebook: https://www.facebook.com/owisebreast 

Px Healthcare  

Px HealthCare (Px) is a visionary force committed to revolutionizing global cancer patient care, founded by medical scientists in 2012. 

Its first digital platform, the OWise breast cancer app, launched in the UK in 2016 building on its success in the Netherlands. Conceived by Px founder, Dr. Anne Bruinvels, a pharmacist with a PhD in biomedical sciences, OWise addresses significant gaps in post-diagnosis cancer patient experiences, currently available for breast cancer in the UK, the Netherlands and the US, and for prostate cancer in the UK. 

Joined by Dr. David Bruinvels, Anne’s brother and a clinical occupational physician specializing in oncology, and a dynamic team of biomedical scientists, software developers, and data scientists, Px embodies collaborative leadership. 

Px Healthcare’s vision is rooted in understanding the challenges patients face and creating impactful solutions. With diverse expertise, including molecular bioscience, clinical occupational medicine, data-science, and advanced software technology and development, Px Healthcare pioneers healthcare solutions that bridge gaps and elevate standards in improving oncology outcomes. 

RWE studies such as RELATE-2 and the OWise cancer apps by Px Healthcare collectively represent a transformative force in cancer research and care. These initiatives underscore a commitment to innovation, patient empowerment, and a vision for a future where healthcare transcends boundaries, making a meaningful impact on the lives of those affected by cancer. 

For more information about Px please visit https://pxhealthcare.com or contact Px Founder and CEO Dr. Anne Bruinvels at anneb@pxhealthcare.com   

LinkedIn: https://linkedin.com/pxhealthcare.